Jean‐Pierre Lotz - Concepedia

Author

Jean‐Pierre Lotz

Sorbonne Université ORCID

Also Known As

A. Lortholary, Alain Lortholary, J Lotz, J P Lotz, J. -P. Lotz, J. LOTZ, J. Lotz, J. P. Lotz, J.-P. Lotz, J.P Lotz

291

Publications

8.6K

Citations

H-Index

Concepts

All Affiliations

Sorbonne Université Hôpital Tenon Assistance Publique – Hôpitaux de Paris Centre Léon Bérard Institut Claudius Regaud

About

Jean‐Pierre Lotz is an author at Sorbonne Université specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	32	5.9K
2	Health Sciences	9	9	412
3	Nursing	1	1	52
4	Biomedical Engineering	1	1	104
5	Biostatistics	1	1	104

Jean‐Pierre Lotz

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study Thierry André, Christophe Tournigand, Olivier Rosmorduc, Annals of Oncology Gastrointestinal OncologyMedicineBiliary CancerPathologyCancer Treatment	2004	381
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer J. Beyer, Peter Albers, Renske Altena, Annals of Oncology	2012	320
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6) F. Maindrault-Gœbel, Christophe Louvet, Thierry André, European Journal of Cancer Oncology5-Fluorouracil RegimenMedicineMetastatic Colorectal CancerColorectal Cancer	1999	287
Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer E. Touboul, Laurent Buffat, Yazid Belkacémi, International Journal of Radiation OncologyBiologyPhysics Surgical OncologyBreast OncologyRadiation TherapyMedicineCancer Recurrence	1999	270
CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer Thierry André, Christophe Louvet, F. Maindrault-Gœbel, European Journal of Cancer OncologyGastrointestinal OncologyMedicineContinuous-infusion 5-FluorouracilColorectal Cancer	1999	268
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Xavier Pivot, P. Koralewski, Jorge Hidalgo, Annals of Oncology Breast OncologyMedicinePharmacologyBreast CancerCancer Treatment	2008	179
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) F. Maindrault-Gœbel, Aimery de Gramont, Christophe Louvet, European Journal of Cancer High-dose Intensity OxaliplatinMedicinePharmacologyColorectal CancerMetastatic Colorectal Cancer	2001	147

Page 1